ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01611090
Recruitment Status : Active, not recruiting
First Posted : June 4, 2012
Last Update Posted : February 8, 2018
Sponsor:
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 19, 2019
  Estimated Study Completion Date : January 19, 2019
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):